ReviewNature reviews. Rheumatology2009
G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis.
Review in Nature reviews. Rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 154 citations in OpenAlex.
- Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2018Trial
- MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.Annals of the rheumatic diseases · 2015Trial
- Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.Annals of the rheumatic diseases · 2013Trial
- High-throughput chemical screen identifies epothilone B in modulating inflammatory bowel disease by triggering neutrophil apoptosis.Genes & diseases · 2027Article
- A strategy to design protein-based antagonists against type I cytokine receptors.PLoS biology · 2024Article
- Neutrophils in Cancer immunotherapy: friends or foes?Molecular cancer · 2024Review
- Extramedullary hematopoiesis in cancer.Experimental & molecular medicine · 2024Review
- The course of cytokine and chemokine gene expression in clinically suspect arthralgia patients during progression to inflammatory arthritis.Rheumatology (Oxford, England) · 2024Article
- Combination treatment with interferon-γ may be a potential strategy to improve the efficacy of cytotherapy for rheumatoid arthritis: A network meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Review
- GM-CSFCell reports · 2022Article
- The Prominent Role of Hematopoietic Peptidyl Arginine Deiminase 4 in Arthritis: Collagen- and Granulocyte Colony-Stimulating Factor-Induced Arthritis Model in C57BL/6 Mice.Arthritis & rheumatology (Hoboken, N.J.) · 2022Article
- Mechanism of Emodin in the Treatment of Rheumatoid Arthritis.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) in subjects with different stages of periodontitis according to the new classification.Journal of applied oral science : revista FOB · 2022Article
- Inhibitory activity of gintonin on inflammation in human IL-1β-stimulated fibroblast-like synoviocytes and collagen-induced arthritis in mice.Journal of ginseng research · 2021Article
- Neutrophil-derived granule cargoes: paving the way for tumor growth and progression.Cancer metastasis reviews · 2021Review
- Brg1 restrains the pro-inflammatory properties of ILC3s and modulates intestinal immunity.Mucosal immunology · 2021Article
- Tumor-Derived Autophagosomes (DRibbles) Activate Human B Cells to Induce Efficient Antigen-Specific Human Memory T-Cell Responses.Frontiers in immunology · 2021Article
- The transition of M-CSF-derived human macrophages to a growth-promoting phenotype.Blood advances · 2020Article
- Application of Mesenchymal Stem Cells in Inflammatory and Fibrotic Diseases.International journal of molecular sciences · 2020Review
- Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.The Lancet. Respiratory medicine · 2020Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are well-recognized regulators of hematopoiesis and have an established role as growth factors in clinical practice. G-CSF and GM-CSF regulate myeloid cell production, differentiation and activation, and might also be important for driving inflammatory responses. Inappropriate engagement of this pathway could be a critical amplification mechanism when maladaptive immune responses predispose to autoimmunity and sterile tissue inflammation. We postulate that antagonism of G-CSF or GM-CSF could represent a novel therapeutic approach for a variety of autoimmune-mediated inflammatory diseases, including rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.